Japan’s Sawai Forecasts Sales Milestone This Year
As Sales Decline In Most Recent 2019 Financial Year
Sales growth through new product launches and increasing the value of its current portfolio will allow Sawai to increase sales by around a tenth this year, the Japanese firm has forecasted, as it also revealed full-year financials for the 12 months ended 31 March 2020.
You may also be interested in...
Sawai has received a raft of generics approvals from Japan’s Ministry of Health, Labour and Welfare, including approval for a tadalafil rival to Cialis and 10 first-time generic approvals.
Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.
Upsher-Smith has acquired US and other territory rights to two specialty product assets of Dr Reddy’s, which appears to be tweaking the commercialization approach of its proprietary products business.